Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Gary J R Cook

9PUBLICATIONS

16CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Mar 31, 2026

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.

Robert O'Shea, Carolyn Horst, Thubeena Manickavasagar

|Apr 05, 2025

PD-L1 imaging with [<sup>99m</sup>Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.

Daniel Johnathan Hughes, Gitasha Chand, Jessica Johnson

|Feb 22, 2024

Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer.

Daniel Johnathan Hughes, Eleni Josephides, Robert O'Shea

|May 31, 2023

Inter-rater and intra-rater agreement of [<sup>99m</sup>Tc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer.

Daniel Johnathan Hughes, Gitasha Chand, Jessica Johnson

|Dec 23, 2022

Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

Daniel Johnathan Hughes, Matthaios Kapiris, Andreja Podvez Nevajda

|Jun 28, 2022

<sup>18</sup>F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer.

Daniel J Hughes, Manil Subesinghe, Benjamin Taylor

Pageof 2

Frequent Collaborators

6 joint publications

Vicky Goh

6 joint publications

Gary J R Cook

3 joint publications

James Spicer

3 joint publications

Gitasha Chand

2 joint publications

Alexandros Georgiou

1 joint publications

Manil Subesinghe

1 joint publications

Benjamin Taylor

1 joint publications

Andrea Bille

1 joint publications

Sophie Papa

1 joint publications

Carolyn Horst

Frequent Collaborators

6 joint publications

Vicky Goh

6 joint publications

Gary J R Cook

3 joint publications

James Spicer

3 joint publications

Gitasha Chand

Top Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on : Aug 14, 2019

Development of a <sup>68</sup>Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a <sup>68</sup>Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on : Feb 03, 2023

See more related videos

Top Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on : Aug 14, 2019

Development of a <sup>68</sup>Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a <sup>68</sup>Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on : Feb 03, 2023

See more related videos